- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02231073
Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism (EEforPD)
Peripheral and Central Postural Disorders in the Elderly
There is emerging research detailing the relationship between balance/gait/falls and cognition. Imaging studies also suggest a link between structural and functional changes in the frontal lobe (a region commonly associated with cognitive function) and mobility. People with Parkinson's disease have important changes in cognitive function that may impact rehabilitation efficacy. Our underlying hypothesis is that cognitive function and frontal lobe connections with the basal ganglia and brainstem posture/locomotor centers are responsible for postural deficits in people with Parkinson's disease and play a role in rehabilitation efficacy. The purpose of this study is to 1) determine if people with Parkinson's disease can improve mobility and/or cognition after partaking in a cognitively challenging mobility exercise program and 2) determine if cognition and brain circuitry deficits predict responsiveness to exercise rehabilitation.
Design: This study is a randomized cross-over controlled intervention to take place at a University Balance Disorders Laboratory. The study participants will be people with Parkinson's disease who meet inclusion criteria for the study. The intervention will be 6 weeks of group exercise (case) and 6 weeks of group education (control). The exercise is a cognitively challenging program based on the Agility Boot Camp for people with PD. The education program is a 6-week program to teach people how to better live with a chronic disease. The primary outcome measure is the MiniBESTest and the secondary outcomes are measures of mobility, cognition and neural imaging.
Discussion: The results from this study will further our understanding of the relationship between cognition and mobility with a focus on brain circuitry as it relates to rehabilitation potential.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Aged 50-90 years old. No musculoskeletal or peripheral or central nervous system disorders (other than idiopathic Parkinson disease (iPD) or parkinsonism) that could significantly affect balance or gait .
Capable of following directions. iPD subjects: UK Brain Bank criteria, i.e., bradykinesia and at least one of the following: rest tremor, muscular rigidity, and postural instability not cause by visual, vestibular, cerebellar or proprioceptive dysfunction. Unilateral onset, response to levodopa.
Parkinsonism subjects: Gait characterized by slow short steps, shuffling gait and may be wide-based, with FoG, postural instability.
Exclusion criteria:
Inability to stand or walk for 2 min without an assistive device Recent changes in medication Excessive use of alcohol or recreational drugs, Contraindications to MRI scans (eg, claustrophobia, metal in body) Intervention subjects will be excluded if: 1) participating in a vigorous exercise program more than 2 x/week, 2) A medical condition that contraindicates exercise participation.
Parkinsonism subjects: iPD and Parkinson plus syndromes such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Syndrome, or Cerebellar Ataxia.
Idiopathic PD subjects: Same as above and deep brain stimulation electrodes. Significant tremor that would interfere withMRI scan.
Control subjects: Will be matched for age and gender to iPD and parkinsonism groups.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercise: Agility Boot Camp-Cognitive
Subjects will participate in an 80-minute, group (6 per group) exercise session led by a certified exercise trainer knowledgeable in the Agility Boot Camp-Cognitive (ABC-C) program for 3x/week for 6 weeks.
The exercise protocol is an adaptation of our Agility Boot Camp (ABC) exercise program for PD.
The exercises are designed as a circuit to challenge movement-skills known to be impaired in PD.
Stations will include: Gait training, PWR Moves ©, Agility course, Lunges, Boxing and Tai Chi.
Each activity was chosen for its inherent focus on multi-directional movements, dynamic postural transitions, axial mobility, big movements and whole body motor sequencing.
Each station (10-20 minutes) has 3 possible progression levels, based on: (1) divided attention with secondary cognitive tasks, (2) response inhibition, (3) limiting external sensory cues, and (4) increasing speed and resistance.
|
Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
|
|
Active Comparator: Education: Living with Parkinson's disease
The Education arm is a chronic disease education program to teach patients how to live better with their chronic condition.
It was developed by our research team to be specific for people with Parkinson's disease.
It will include content and discussion of topics such as sleep, nutrition, and medication management.
Classes will consist of a group of subjects (up to 6) meeting with the trainer for 90-minute session, once a week for six weeks.
In order to match dose of the education intervention with the exercise intervention, participants will be provided relaxation tapes to be used at home 5 times per week for 30 minutes for an overall education dose of 240 minutes; similar to the exercise dose.
|
Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Mini-BESTest score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
The Mini-BESTest assesses dynamic balance via a 14-item test that measures multiple domains of balance including anticipatory postural adjustments, reactive postural control, sensory orientation, dynamic gait.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in MDS-UPDRS score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
The Unified Parkinson's Disease Rating Scale Motor Subscale III is a 10-minute assessment of motor signs related to severity of PD.
If the investigators have trouble recruiting subjects of similar severity in the 2 groups, they will use the Postural Instability and Gait Disability(PIGD) Subscore (Items 27-30) as a covariate in data analysis.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
|
Change in New Freezing of Gait questionnaire (NFOGQ) score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
The New FoG of Gait Questionnaire will be used to identify 'freezers' (score >3).
NFOGQ is a self-report measure that begins with the presentation of a short (30-s) video to illustrate FoG during walking turning and starting gait and then follows with questions related to frequency and duration of each type of FoG episode.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
|
Change in PDQ-39 score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
the Parkinson's Disease Quality of Life questionnaire with 39 questions reflecting 8 domains of quality of life (Mobility, ADL's, Emotional well-being, Stigma, Social support, Cognition, Communication, and Bodily discomfort).
Each item scores from 0 (never) to 4 (always).
Subscale scores and a summary index representing the global health-related quality of life will be calculated, with higher scores representing worse quality of life.
Convergent validity is very good and discriminative validity for PD severity levels has been established.
The PDQ will reflect limitations to participation in community mobility.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
|
Change in Activities of Balance Confidence (ABC) questionnaire score
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Activities of Balance Confidence (ABC) questionnaire consists of 16 questions about how balance confidence limits participating in the community such as riding an escalator, walking in a parking lot and replacing a light.
Subjects indicate their confidence from 0% to 100% they have in their balance when they imagine doing these tasks.
A score of 80% indicates an average level of physical functioning for older adults.
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
|
Change in instrumented gait and balance measures
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Balance: Postural sway during quiet stance with and without a cognitive task. Gait: Spatial and temporal gait metrics will be collected during walking, while wearing the Opal inertial sensors, with and without a cognitive task. Turning: Smoothness of turning measure during 1 min turning in place (360 degree) and turns during 2 min walk, with and without a cognitive task. |
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
|
Neural Imaging
Time Frame: Baseline
|
DTI: High angular resolution diffusion imaging to assess white matter microstructure. Structural connectivity of the locomotor network will be assessed using probabilistic tractography. rsfcMRI: An indirect assessment of communication between spatially disparate neural regions. Analysis is restricted to neural regions comprising the locomotor network including the supplementary motor area, subthalamic nuclei, mesencephalic locomotor regions (pedunculopontine and cuneiform nuclei), and the midline cerebellar locomotor region |
Baseline
|
|
Change in Cognitive measures
Time Frame: Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
A battery of tests to measure different cognitive domains: inhibition (stroop, flankers, go/nogo, stop signal), shifting (set-shifting, trail making), updating (dot counting task), visual-spatial (judgement of line orientation), general cognition (SCOPA-COG), and other (social norms questionnaire, social behavior rating scale, simple reaction time test).
|
Three timepoints; baseline, 6 weeks (after Arm 1), 12 weeks (after Arm 2)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Fay B Horak, PhD, Oregon Health and Science University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4131
- 2R01AG006457 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
EicOsis Human Health Inc.University of California, Davis; Michael J. Fox Foundation for Parkinson's...RecruitingParkinson's Disease (PD)United States
-
University of Kansas Medical CenterNot yet recruitingParkinson's Disease (PD)United States
-
AbbVieRecruiting
-
University Hospital Schleswig-HolsteinUniversity of Kiel; University of Cologne; University Hospital, Bonn; Philipps...Not yet recruitingParkinson's Disease (PD)
-
InvicroMerck Sharp & Dohme LLCRecruitingParkinson's Disease | Parkinson's Disease (PD) | Parkinson's Disease (Disorder)United States
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Guangzhou Henovcom Bioscience Co. Ltd.Frontage Clinical Services, Inc.Active, not recruitingParkinson's Disease (PD)United States
-
Universitätsklinikum Hamburg-EppendorfUniversity of TwenteRecruitingParkinson's Disease | Deep Brain StimulationGermany
-
Mission TherapeuticsMichael J. Fox Foundation for Parkinson's Research; Parkinson's UKRecruitingParkinson's Disease (PD) | Early Stage Parkinson's Disease | Mild to Moderate Parkinson's DiseaseUnited Kingdom
Clinical Trials on Exercise and Education for Parkinson's Disease
-
University College CorkActive, not recruiting
-
Parkinson's FoundationIndiana University; The Parkinson Study Group; Navitas Clinical Research, Inc; Fulgent...Active, not recruitingParkinson's Disease and ParkinsonismUnited States
-
Parkinson's FoundationIndiana University; The Parkinson Study Group; Fulgent GeneticsRecruitingParkinson's DiseaseUnited States, Israel, Canada
-
Sun Life Financial Movement Disorders Research...Completed
-
VA Office of Research and DevelopmentCompleted
-
Clemson UniversityCompletedParkinson's Disease
-
Korea Health Industry Development InstituteCompletedParkinson DiseaseKorea, Republic of
-
Stony Brook UniversityParkinson's Disease FoundationCompletedParkinson DiseaseUnited States
-
MedtronicNeuroCompletedParkinson DiseaseBrazil, China
-
University of ManitobaCompleted